Amgen Inc. (AMGN)
| Previous close | 269.38 |
| Open | 265.72 |
| Bid | 268.52 x 100 |
| Ask | 270.09 x 100 |
| Day's range | 265.72 - 270.76 |
| 52-week range | 211.71 - 329.72 |
| Volume | |
| Avg. volume | 2,957,317 |
| Market cap | 144.374B |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | 21.53 |
| EPS (TTM) | 12.50 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 9.00 (3.34%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | 306.20 |
PR NewswireAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
ZacksAnalysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
